ImmunityBio (NASDAQ:IBRX) Sets New 52-Week High – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price hit a new 52-week high during trading on Friday . The stock traded as high as $4.94 and last traded at $4.5850, with a volume of 41968992 shares changing hands. The stock had previously closed at $3.95.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports preliminary net product revenue of ~$113M for 2025 (a ~700% YoY increase), a major inflection in commercial sales that underpins today’s rally. ImmunityBio Reports Continued Execution and Sales Momentum
• Positive Sentiment: Media coverage highlights the 700% revenue surge and frames it as a catalyst for renewed investor interest and momentum. ImmunityBio (IBRX) Stock Surges 30% on 700% Revenue Growth
• Positive Sentiment: Updated QUILT‑106 CAR‑NK data: durable complete responses up to ~15 months in Waldenström lymphoma, which supports pipeline value beyond Anktiva. ImmunityBio Announces Durable Complete Response of 15 Months
• Positive Sentiment: QUILT‑2.005 (first‑line BCG‑naïve NMIBC) enrollment >85% and company now anticipates full enrollment by Q2 2026 with a potential BLA submission by year‑end — accelerates regulatory pathway for a label expansion. ImmunityBio Advances First-Line BCG Naive NMIBC Program
• Positive Sentiment: Anktiva received accelerated approval in Saudi Arabia and continued international approvals/expansions are cited as drivers of the global sales ramp. Accelerated Saudi approval for ImmunityBio’s Anktiva
• Positive Sentiment: H.C. Wainwright and other analysts/publications are affirming buy stances and positive outlooks on Anktiva/label expansion potential, adding credibility to the story. H.C Wainwright Asserts Buy Stance
• Neutral Sentiment: ImmunityBio presented at the J.P. Morgan Healthcare Conference — useful for incremental detail and management commentary but not a single clear stock catalyst. ImmunityBio Presents at J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Hedge‑fund and institutional interest (coverage noting Citadel, etc.) is increasing — signals positioning but not a direct operational change. ImmunityBio’s 700% Revenue Boom Becomes Citadel’s Latest I-Told-You-So
• Negative Sentiment: Some coverage warns the rally is extended and suggests profit‑taking; investors should weigh fast appreciation, remaining net losses and execution risk before buying. ImmunityBio Extends Gains to 10th Day — Time to Book Profits?

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on IBRX shares. D. Boral Capital reissued a “buy” rating and issued a $24.00 price objective on shares of ImmunityBio in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Finally, Jefferies Financial Group lifted their price target on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

ImmunityBio Price Performance

The company has a market capitalization of $5.44 billion, a price-to-earnings ratio of -13.46 and a beta of 0.03. The firm’s fifty day moving average price is $2.29 and its 200-day moving average price is $2.44.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to analyst estimates of $31.88 million. On average, research analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Slow Capital Inc. bought a new position in ImmunityBio in the 3rd quarter valued at approximately $25,000. Truist Financial Corp acquired a new position in ImmunityBio in the 3rd quarter valued at approximately $27,000. Swiss Life Asset Management Ltd acquired a new position in ImmunityBio in the 3rd quarter valued at approximately $27,000. Diversify Advisory Services LLC bought a new position in shares of ImmunityBio during the second quarter valued at $27,000. Finally, Financial Enhancement Group LLC acquired a new position in shares of ImmunityBio during the second quarter worth $28,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.